Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Perampanel in Chinese Healthy Subjects
NCT03424564Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Mar 2018
- Primary completion
- May 2018
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of perampanel in epilepsy (4 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Maximum Observed Concentration, Time to Maximum Concentration and 12 more. Started Mar 2018; status: completed.
02
Drugs
perampanel
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT03424564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03424564.